Result of EGM

Cambridge Antibody Tech Group PLC
20 October 2003



03/CAT/28

FOR IMMEDIATE RELEASE

20 October 2003

For further information contact:        Weber Shandwick Square Mile (Europe)
Cambridge Antibody Technology           Tel: [phone]
Tel: [phone]               Kevin Smith
Peter Chambre, Chief Executive Officer  Rachel Lankester
John Aston, Chief Financial Officer
Rowena Gardner, Director of Corporate
Communications
                                        BMC Communications/The Trout Group (USA)
                                        Tel: [phone]
                                        Brad Miles, ext 17 (media)
                                        Brandon Lewis, ext 15 (investors)
                                      

CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
ANNOUNCES RESULT OF EGM

Cambridge, UK ... Cambridge Antibody Technology (LSE:CAT; NASDAQ:CATG) announces
that at its Extraordinary General Meeting, held earlier today, all resolutions
were duly passed.

                                     -ENDS-

Cambridge Antibody Technology (CAT):

   • CAT is a UK-based biotechnology company using its proprietary
    technologies and capabilities in human monoclonal antibodies for drug
    discovery and drug development. Based near Cambridge, England, CAT currently
    employs around 290 people.
   • CAT is a leader in the discovery and development of human therapeutic
    antibodies and has an advanced proprietary platform technology for rapidly
    isolating human monoclonal antibodies using phage display and ribosome
    display systems. CAT has extensive phage antibody libraries, currently
    incorporating more than 100 billion distinct antibodies. These libraries
    form the basis for the Company's strategy to develop a portfolio of
    antibody-based drugs.
   • HUMIRA, the leading CAT-derived antibody, isolated and optimised in
    collaboration with Abbott has been approved by the US Food and Drug
    Administration for marketing in the US and by the European Commission for
    marketing in the EU as a treatment for rheumatoid arthritis.
   • Eight further CAT-derived human therapeutic antibodies are at various
    stages of clinical trials. There are five candidate therapeutic antibodies
    in pre-clinical development.
   • CAT has alliances with a number of pharmaceutical and biotechnology
    companies to discover, develop and commercialise human monoclonal
    antibody-based products. CAT has co-development programmes with Amgen,
    Amrad, Elan and Genzyme.
   • CAT has also licensed its proprietary technologies to several companies.
    CAT's licensees include: Abbott, Amgen, Chugai, Human Genome Sciences, Merck
    & Co, Pfizer and Wyeth Research.
   • CAT is listed on the London Stock Exchange and on NASDAQ since June
    2001. CAT raised £41m in its IPO in March 1997 and £93m in a secondary
    offering in March 2000.

Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All statements
other than statements of historical facts included in this press release may be
forward looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934. These forward looking statements are based on numerous
assumptions regarding the company's present and future business strategies and
the environment in which the company will operate in the future. Certain factors
that could cause the company's actual results, performance or achievements to
differ materially from those in the forward looking statements include: market
conditions, CAT's ability to enter into and maintain collaborative arrangements,
success of product candidates in clinical trials, regulatory developments and
competition. We caution investors not to place undue reliance on the forward
looking statements contained in this press release. These statements speak only
as of the date of this press release, and we undertake no obligation to update
or revise the statements.




                      This information is provided by RNS
            The company news service from the London Stock Exchange